Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.43 |
| ▸ | TACR1 | P25103 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
| ▸ | CCR2 | P41597 | 3/20 | 0.39 |
| ▸ | MTTP | P55157 | 1/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3954533 | 0.89 | CNR2 (0.39) | — | |
| SCHEMBL3955844 | 0.88 | SLC6A2 (0.43) | OPRM1OPRL1TACR1SLC6A2SLC6A4 | |
| SCHEMBL3955939 | 0.87 | CYP2C9 (0.42) | — | |
| SCHEMBL3958040 | 0.85 | SLC6A2 (0.48) | OPRM1OPRL1TACR1SLC6A2SLC6A4 | |
| SCHEMBL3961259 | 0.84 | KMT2A (0.41) | — | |
| SCHEMBL3961166 | 0.83 | KLKB1 (0.44) | MTORTACR1MCHR1 | |
| SCHEMBL3951075 | 0.82 | CYP2C9 (0.44) | OPRM1OPRL1SLC6A2SLC6A4 | |
| SCHEMBL13712079 | 0.80 | SLC6A2 (0.49) | MTOROPRM1OPRL1SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL3958193 | 0.79 | SLC6A2 (0.48) | MTORSLC6A2SLC6A4 | |
| SCHEMBL3955063 | 0.76 | SLC1A2 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227585-A1 | SUBSTITUTED N-HETEROCYCLE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2009-09-10 | — | — | US | disclosed |
| US-7550485-B2 | Substituted N-heterocycle derivatives and methods of their use | WYETH (US) | 2009-06-23 | — | — | US | disclosed |
| US-7550456-B2 | Substituted aryl cycloalkanoyl derivatives and methods of their use | WYETH (US) | 2009-06-23 | — | — | US | disclosed |
| US-7524846-B2 | Arylalkyl- and cycloalkylalkyl-piperazine derivatives and methods of their use | WYETH (US) | 2009-04-28 | — | — | US | disclosed |
| US-7491723-B2 | Alkanol and cycloalkanol-amine derivatives and methods of their use | WYETH (US) | 2009-02-17 | — | — | US | disclosed |
| US-7419980-B2 | Fused-aryl and heteroaryl derivatives and methods of their use | WYETH (US) | 2008-09-02 | — | — | US | disclosed |
| US-7402698-B2 | Secondary amino-and cycloamino-cycloalkanol derivatives and methods of their use | WYETH (US) | 2008-07-22 | — | — | US | disclosed |
| US-20080153826-A1 | SUBSTITUTED ARYL CYCLOALKANOL DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2008-06-26 | — | — | US | disclosed |
| US-7365076-B2 | Substituted aryl cycloalkanol derivatives and methods of their use | WYETH (US) | 2008-04-29 | — | — | US | disclosed |
| CN-1897950-A | Fused aryl and heteroaryl derivatives and methods of use thereof | WYETH CORP (US) | 2007-01-17 | — | — | CN | disclosed |
| CN-1897946-A | 1- 2' (1, 4'-biperidin-1'-yl)-1- (phenyl) -ethyl cyclohexanol derivatives as monoamine reuptake modulators for the treatment of visomotor symptoms | WYETH CORP (US) | 2007-01-17 | — | — | CN | disclosed |
| CN-1898222-A | Substituted aryl cycloalkanol derivatives and methods of their use | WYETH CORP (US) | 2007-01-17 | — | — | CN | disclosed |
| US-20050234058-A1 | Secondary amino-and cycloamino-cycloalkanol derivatives and methods of their use | WYETH (US) | 2005-10-20 | — | — | US | disclosed |
| US-20050192283-A1 | Fused-aryl and heteroaryl derivatives and methods of their use | WYETH (US) | 2005-09-01 | — | — | US | disclosed |
| US-20050187251-A1 | Substituted N-heterocycle derivatives and methods of their use | WYETH (US) | 2005-08-25 | — | — | US | disclosed |
| US-20050171115-A1 | Alkanol and cycloalkanol-amine derivatives and methods of their use | WYETH (US) | 2005-08-04 | — | — | US | disclosed |
| US-20050148595-A1 | Arylalkyl-and cycloalkylalkyl-piperazine derivatives and methods of their use | WYETH (US) | 2005-07-07 | — | — | US | disclosed |
| US-20050143579-A1 | Substituted aryl cycloalkanol derivatives and methods of their use | WYETH (US) | 2005-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143579-A1 | Substituted aryl cycloalkanol derivatives and methods of their use | HTR3A, MAOA, FAAH | MTOR 2994/4885OPRM1 215/4885OPRL1 40/4885 |
| US-20050148595-A1 | Arylalkyl-and cycloalkylalkyl-piperazine derivatives and methods of their use | GLS, HTR5A, HTR3A | MTOR 3380/4885OPRM1 195/4885OPRL1 17/4885 |
| US-20080153826-A1 | SUBSTITUTED ARYL CYCLOALKANOL DERIVATIVES AND METHODS OF THEIR USE | HTR3A, MAOA, GLS | MTOR 2784/4885OPRM1 227/4885OPRL1 59/4885 |
| US-20050171115-A1 | Alkanol and cycloalkanol-amine derivatives and methods of their use | FAAH, HTR3A, MAOA | MTOR 2409/4885OPRM1 178/4885OPRL1 73/4885 |
| US-20090227585-A1 | SUBSTITUTED N-HETEROCYCLE DERIVATIVES AND METHODS OF THEIR USE | MAOA, MAOB, SDHA | MTOR 1139/4885OPRM1 77/4885OPRL1 50/4885 |
| US-20050234058-A1 | Secondary amino-and cycloamino-cycloalkanol derivatives and methods of their use | ASNS, GLS, GYS1 | MTOR 1449/4885OPRM1 256/4885OPRL1 66/4885 |
| US-20050187251-A1 | Substituted N-heterocycle derivatives and methods of their use | MAOA, MAOB, SDHA | MTOR 1139/4885OPRM1 77/4885OPRL1 50/4885 |
| US-20050192283-A1 | Fused-aryl and heteroaryl derivatives and methods of their use | COMT, MAOA, HTR3A | MTOR 2921/4885OPRM1 90/4885OPRL1 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.